- INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN FOR WHICH THE PI IS FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
-
A composition in the form of an injectable aqueous solution, whose pH consists from 6.0 to 8.0, including at least: a basal insulin whose isoelectric point includes from 5.8 to 8.5; a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals Hy, the co-polyamino-acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy according to the following formula I:
- -
-
Paragraph 0497-0499
(2021/01/19)
-
- METHOD FOR THE SYNTHESIS OF AN N-ACYL COMPOUND WITHOUT THE USE OF ORGANIC SOLVENT OR ACID CHLORIDE
-
Disclosed is a method for the synthesis of N-acyl proline or N-acyl 3-hydroxy proline by way of the amide formation of a fatty acid at a high temperature, an intermediate composition of the method, and a cosmetic composition containing same.
- -
-
Paragraph 0099-0100
(2020/05/06)
-
- INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
-
In one embodiment, the composition according to the invention is characterized in that the co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical -Hy is chosen among the co-polyamino acids according to formula XXXb hereinafter: wherein, D represents, independently, either a group —CH2— (aspartic acid) or a group —CH2—CH2— (glutamic acid),X represents a cationic entity chosen in the group comprising alkali cations,Rb and Rb′, identical or different, are either a hydrophobic radical -Hy, or a radical chosen in the group consisting of an H, a C2 to C10 linear acyl group, a C3 to C10 branched acyl group, a benzyl, a terminal “amino acid” unit and a pyroglutamate, at least one of Rb and R′b is a hydrophobic radical -Hy,Q and Hy are as defined above.n+m represents the degree of polymerization DP of the co-polyamino acid, namely the mean number of monomeric units per co-polyamino acid chain and 5≤n+m≤250.
- -
-
Paragraph 1004; 1005; 1006; 1007; 1017-1021
(2019/09/20)
-
- Synthesis of: N-acyl amide natural products using a versatile adenylating biocatalyst
-
Natural products are secondary metabolites produced by many different organisms such as bacteria, fungi and plants. These biologically active molecules have been widely exploited for clinical application. Here we investigate TamA, a key enzyme from the biosynthetic pathway of tambjamine YP1, an acylated bipyrrole that is produced by the marine microorganism Pseudoalteromonas tunicata. TamA is a didomain enzyme composed of a catalytic adenylation (ANL) and an acyl carrier protein (ACP) domain that together control the fatty acid chain length of the YP1. Here we show that the TamA ANL domain alone can be used to generate a range of acyl adenylates that can be captured by a number of amines thus leading to the production of a series of fatty N-acyl amides. We exploit this biocatalytic promiscuity to produce the recently discovered class of N-acyl histidine amide natural products from Legionella pneumophila.
- Marchetti, Piera M.,Richardson, Shona M.,Kariem, Noor M.,Campopiano, Dominic J.
-
supporting information
p. 1192 - 1196
(2019/07/31)
-
- COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE
-
Physically stable compositions in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, includes at least: a) human glucagon andb) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In one embodiment, the compositions further comprise a gut hormone.
- -
-
Paragraph 0967-0970
(2019/09/20)
-
- COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID
-
A composition in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, including at least: a) amylin, an amylin receptor agonist or an amylin analogue;b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid being constituted of glutamic or aspartic units and said hydrophobic radicals Hy being according to formula I below: [in-line-formulae]*?GpR?r?GpA?a?GpC)p ??Formula I[/in-line-formulae] wherein the composition does not comprise a basal insulin the isoelectric point pI of which is comprised from 5.8 to 8.5. It also relates to a composition wherein it further includes prandial insulin.
- -
-
Paragraph 1313-1317; 1330-1333
(2019/09/20)
-
- COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID
-
Physically stable compositions in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, having at least: human glucagon and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, in one embodiment, the compositions according to the invention further includes a gastrointestinal hormone.
- -
-
Paragraph 1535-1539; 1555-1560
(2019/09/20)
-
- COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID
-
An injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: [in-line-formulae]?GpR?r?GpA?a?GpC)p ??I[/in-line-formulae] wherein the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition wherein it moreover comprises a prandial insulin.
- -
-
Paragraph 0908-0911; 0924-0927
(2018/07/31)
-
- Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
-
A physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0: a basal insulin of which the isoelectric point (pI) is from 5.8 to 8.5, a prandial insulin or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
- -
-
Paragraph 0628-0631; 0644-0647
(2018/01/09)
-
- Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
-
An injectable aqueous solution, the pH of which is from 6.0 to 8.0, having at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In an embodiment, the compositions have, in addition, a gastrointestinal hormone.
- -
-
Paragraph 0743; 0744; 0745; 0746; 0759; 0760; 0761; 0762
(2018/01/09)
-
- Moisturizer and Cosmetic Agent Containing Same
-
Provided is a moisturizer having hygroscopicity and water retention ability, and also provided is a composition superior in antiseptic property and feeling on application, in addition to moisturizing property, and free of coloration and odorization. A moisturizer containing acylproline represented by the formula (1) wherein an acyl group represented by R1—CO— is an acyl group derived from a saturated or unsaturated fatty acid having 3-23 carbon atoms, or a salt thereof, and a composition containing (A) acylproline represented by the above formula (1) or a salt thereof and (B) bisphosphonate.
- -
-
Paragraph 0096; 0098
(2015/04/28)
-
- COSMETIC COMPOSITION
-
Provided is a composition that masks the odor characteristic of anisic acid or phenylalkanol, is superior in appearance and texture on application, and provides moist feeling to the skin after application. Specifically, a composition containing (A) acyl proline represented by the formula (I) or a salt thereof, and (B) one or more kinds selected from anisic acid and phenylalkanol is provided.
- -
-
Paragraph 0075; 0077
(2015/02/18)
-
- Luliberin analogues exhibiting a cytotoxic effect on tumor cells in vitro
-
Luliberin analogues modified at the N-terminus were synthesized to search for drugs exerting a cytotoxic effect on cells of hormone-dependent tumors. A synthetic scheme effective in the preparation of analogues containing fatty acid residues was proposed. The cytotoxic effect of the peptides was studied on a number of cell lines of human tumors in vitro. The dependence of the antitumor effect on the length of peptide chain, amino acid sequence, and structure of the N-terminal group was demonstrated. Modification with palmitic acid was found to result in highly active compounds in the case of analogues containing more than ten aa, whereas modifications with lauric, caproic, or trimethylacetic acid led to compounds with significantly lower activities. Analogues of luliberin containing a palmitic acid residue and effectively inhibiting the growth of tumor cells in vitro were synthesized. Pleiades Publishing, Inc., 2006.
- Burov,Yablokova,Dorosh,Shkarubskaya,Blank,Epstein,Fridkin
-
p. 413 - 419
(2008/02/11)
-